Notably, our recent study has also found that the TNF-α antagonist, etanercept, successfully relieves SJS/TEN symptoms with an increase in frequencies of CD4+CD25+FOXP3+ Tregs after treatment (127). Here, TNF is linked to toxic epidermal necrolysis.